Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glunomab
- Development stage
- Preclinical
- Lead developer
- Lys Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Glunomab is a monoclonal antibody designed to inhibit the specific interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), particularly the GluN1 (NMDAR1) subunit. In the central nervous system, tPA acts as a neuromodulator that binds to NMDAr, enhancing its activity and potentially driving neuroinflammation and neurodegeneration in conditions like Parkinson's disease (PD). Glunomab blocks this interaction without interfering with the physiological catalytic activity of tPA or the normal ionotropic function of the NMDAr. By preventing tPA-mediated NMDAr overactivation, the antibody reduces microglia activation, immune cell infiltration, and blood-brain barrier permeability. A humanized version of the antibody, LYS241, is being developed by Lys Therapeutics and is currently in IND/CTA-enabling studies for the treatment of Parkinson's disease, with potential applications in other neurological disorders such as multiple sclerosis and stroke.
- Other names
- glunomab
02
Targets
GluN1 (Glutamate ionotropic receptor NMDA type subunit 1)
Beyond the preview
Go deeper on glunomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glunomab.